Clinical trials
Peripheral Blood Stem Cell Transplantation clinical trials
Below are recruiting peripheral blood stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 177 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT07340723RecruitingPhase 2
New treatment study for grade II acute GVHD after transplant
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07101497RecruitingPhase 2
BN104 as maintenance therapy after stem cell transplant for leukemia
This trial tests a new drug called BN104 to help keep leukemia from coming back after a stem cell transplant. It's for people with certain types of acute leukemia that have specific gene changes.
Suzhou, JiangsuAges 12 years+ - NCT06972641RecruitingPhase 2/Phase 3
Gene-based maintenance therapy after stem cell transplant
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 14–75 - NCT07148947RecruitingPhase 2
Pacritinib with standard care before stem cell transplant for MPN
This trial tests adding pacritinib to standard hypomethylating agents (azacitidine or decitabine) before a stem cell transplant for people with myeloproliferative neoplasms (MPN) that have progressed to a more advanced phase.
Seattle, WashingtonAges 18 years+ - NCT05827549RecruitingPhase 2
Blinatumomab for relapsed ALL, matched by risk group
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
DaeguAges 1–22 - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Birmingham, AlabamaAges 12 months–30 years - NCT03630211RecruitingPhase 2
Study of stem cell transplant for systemic sclerosis in youth
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Pittsburgh, PennsylvaniaAges 8–60 - NCT03909412RecruitingPhase 1
Carfilzomib chemo to help you collect stem cells for transplant
This Phase 1 study tests a carfilzomib-based treatment plan to help people with multiple myeloma collect enough stem cells for an autologous (using your own) stem cell transplant. It’s mainly about whether this mobilization approach works and is safe for you.
Hackensack, New JerseyAges 18 years+ - NCT04180059RecruitingPhase 1
Anti-DP treatment after stem cell transplant to prevent relapse
This early-phase trial tests an anti-DP medicine given after an allogeneic (donor) stem cell transplant. It aims to improve outcomes by targeting immune cells linked to certain transplant match types and reducing relapse risk.
NantesAges 18–75 - NCT04628026RecruitingPhase 3
Venetoclax plus chemotherapy for new AML or high-risk MDS
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
InnsbruckAges 18–75 - NCT05124288Recruiting
Study immune changes after AML relapse after bone marrow transplant
This study looks at how the immune system changes when acute myeloid leukemia (AML) comes back after a donor stem cell transplant. It may help researchers create more personalized treatment plans and future guidelines for how to care for people in this situation.
Milan, MilanoAges 18 years+ - NCT05797272Recruiting
In-utero stem cell treatment for Bart’s hydrops
This trial studies whether giving hematopoietic (blood-forming) stem cells while the baby is still in the womb can treat fetuses with Bart’s hydrops fetalis syndrome. It aims to improve outcomes after prenatal intervention in carefully selected pregnancies.
ShatinAges 18 years+ - NCT06265584RecruitingPhase 2
Using ATG to prevent graft-versus-host disease after stem cell transplant
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
Birmingham, AlabamaAges 18–75 - NCT06279676Recruiting
Improving women's health after donor stem cell transplant
This study looks at improving health after a stem cell transplant from a donor. It focuses on women's health issues after the transplant.
Montreal, QuebecAges 18 years+ - NCT06315309RecruitingPhase 2
Two-step ATG to prevent GVHD after stem cell transplant
This trial tests a two-step use of ATG (a drug that calms immune cells) to help prevent graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from a donor. It may be an option for people with certain blood cancers or disorders who are getting a strong, marrow-clearing transplant.
Birmingham, AlabamaAges 18–60 - NCT06458244Recruiting
Stem cell transplant for high-risk CBF-AML
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06575296RecruitingPhase 1
Revumenib after stem cell transplant for acute leukemia
This trial tests a drug called revumenib to help keep leukemia from coming back after a stem cell transplant. It is for people with specific genetic types of acute leukemia who have recently had or will soon have a transplant.
Duarte, CaliforniaAges 2 years+ - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT06756061RecruitingPhase 2
Ruxolitinib and steroids for chronic graft-versus-host disease
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
Seoul, Banpo-daero/Seocho-guAges 19 years+ - NCT06869265RecruitingPhase 2
Thiotepa added to standard chemo before a stem cell transplant for older adults with high-risk AML
This trial tests whether adding a drug called thiotepa to the usual chemotherapy (busulfan and fludarabine) before a half-matched stem cell transplant can safely and effectively treat older adults (55–70) with high-risk AML.
Beijing, Beijing MunicipalityAges 55–70 - NCT06879847Recruiting
Clinical trial of radiation and chemotherapy before stem cell transplant for hard-to-treat AML
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Suzhou, JiangsuAges 14–70 - NCT07059026Recruiting
Thrombotic microangiopathy after stem cell transplant in adults
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
Buenos AiresAges 18 years+
Hear when a new Peripheral Blood Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peripheral blood stem cell transplantation?
- Yes. Clin2 currently lists 177 recruiting peripheral blood stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peripheral blood stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peripheral blood stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.